Catalyst Pharmaceutical (CPRX -62%) craters after saying earlier that CPP-109, its potential cocaine addiction treatment, failed to meet its primary endpoint versus a placebo in Phase II studies. The data also showed that two key secondary endpoints, a significantly larger increase in cocaine negative urines and a significant decrease in the weekly fraction of use days in medication-treated subjects, also were not met.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs